Glofitamab, CAS 2229047-91-8

Product Description: Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell lymphoma[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Hutchings M, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021;39(18):1959-1970. /[2]Bröske AE, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6(3):1025-1037.

CAS Number: 2229047-91-8

Molecular Weight: N/A

Compound Purity: 99.80

Research Area: Cancer

Solubility: H2O

Target: CD20

• Artikelnummer: MEXHY-P99024-5
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99024-5
• Green Labware: Nein
• Verpackungseinheit: 5 mg
• Mengeneinheit: STK